Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Study of CoV-2 mRNA Vaccine for High Risk Populations

Next Previous
Trial Profile

Clinical Study of CoV-2 mRNA Vaccine for High Risk Populations

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2020

Print Profile Download Citation

At a glance

  • Drugs MRNA Coronavirus vaccine eTheRNA Immunotherapies (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions

    • Most Recent Events

    • 30 Mar 2020 New trial record
    • 24 Mar 2020 According to an eTheRNA Immunotherapies media release, eTheRNA and its partners EpiVax, Nexelis, REPROCELL and CEV have extensive experience in the mRNA vaccine field and this will help accelerate progress towards clinical trials with patient enrolment expected in early 2021.

Trial Overview

Purpose

This study will investigate mRNA covid-2019 vaccine in high rish population.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections prevention -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Affiliations eTheRNA Immunotherapies

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Unknown
  • Focus Adverse reactions

Interventions

Drugs Route Formulation
MRNA Coronavirus vaccine eTheRNA ImmunotherapiesPrimary Drug Nasal
-

mRNA COVID-2019 vaccine

mRNA COVID-2019 vaccine

Trial History

Event Date Event Type Comment
30 Mar 2020 New trial record New trial record Updated 30 Mar 2020
24 Mar 2020 Other trial event According to an eTheRNA Immunotherapies media release, eTheRNA and its partners EpiVax, Nexelis, REPROCELL and CEV have extensive experience in the mRNA vaccine field and this will help accelerate progress towards clinical trials with patient enrolment expected in early 2021. Updated 30 Mar 2020

References

  1. eTheRNA Immunotherapies. eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine for High Risk Populations. Media-Rel 2020;.

    Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG
Legal
Back to top